The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Fáber as a member of the Executive Board for an additional five-year term, which will now run through December 31, 2031. Dr. Fáber, who holds a Ph.D. in polymer chemistry from the Technical University of Munich, joined the company as a scientist in 2002 and has held several management positions. He was appointed to the Executive Board in January 2019, where he is responsible for the Bioprocess Solutions Division.
This leadership continuity comes as Sartorius positions itself within the critical biopharmaceutical sector. The company serves as a leading international partner to biopharmaceutical research and manufacturing industries. Its operations are divided into two main divisions: Lab Products & Services, which focuses on innovative laboratory instruments and consumables, and the Bioprocess Solutions Division led by Dr. Fáber. This division provides a broad portfolio of single-use solutions aimed at making the production of biotech drugs, vaccines, and cell and gene therapies safer, faster, and more sustainable.
The extension of Dr. Fáber's tenure signals stability in the company's strategic direction. Sartorius, headquartered in Göttingen, Germany, maintains a significant global footprint with approximately 60 production and sales locations worldwide. In 2025, the company reported sales revenue of around 3.5 billion euros and employs more than 14,000 people globally. The company has a history of growing its portfolio through acquisitions of complementary technologies.
Investors and industry observers can monitor the company's performance through its published financial calendar. Key upcoming dates include the publication of first-quarter results on April 23, 2026, half-year results on July 23, 2026, and nine-month results on October 22, 2026. Further details about the company's leadership and operations are available through its official channels, including its newsroom and professional network profiles. The decision by the Supervisory Board underscores confidence in the current executive leadership as Sartorius continues to support the evolving needs of the global biopharmaceutical industry.
